opc 28326 has been researched along with yohimbine in 4 studies
| Studies (opc 28326) | Trials (opc 28326) | Recent Studies (post-2010) (opc 28326) | Studies (yohimbine) | Trials (yohimbine) | Recent Studies (post-2010) (yohimbine) |
|---|---|---|---|---|---|
| 9 | 1 | 1 | 5,893 | 253 | 532 |
| Protein | Taxonomy | opc 28326 (IC50) | yohimbine (IC50) |
|---|---|---|---|
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0353 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 1.02 | |
| D(2) dopamine receptor | Homo sapiens (human) | 2.06 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 1.3 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0428 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0466 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.126 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0682 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0682 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0682 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 1.3 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.013 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.126 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.074 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 1.3 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 1.689 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujiki, H; Imaizumi, T; Kambayashi, J; Kimura, Y; Kishi, M; Mori, T; Orito, K; Shimizu, H; Tanaka, M; Teramoto, S; Tominaga, M; Yoshida, K | 1 |
| Chen, R; Kambayashi, JI; Li, J; Lockyer, S; Sun, B; Yoshitake, M | 1 |
| Hashimoto, A; Imaizumi, T; Kambe, T; Kishi, M; Mori, T; Nakazawa, T; Orito, K | 1 |
| Chiba, S; Fukui, D; Yang, XP | 1 |
4 other study(ies) available for opc 28326 and yohimbine
| Article | Year |
|---|---|
Mechanisms of action of OPC-28326, a selective hindlimb vasodilator.
Topics: Adrenergic Antagonists; Anesthesia; Aniline Compounds; Animals; Blood Pressure; Brimonidine Tartrate; Dogs; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Femoral Artery; Hemodynamics; Hindlimb; In Vitro Techniques; Male; Perfusion; Phenylephrine; Piperidines; Prazosin; Quinoxalines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Vasodilator Agents; Yohimbine | 1999 |
OPC-28326, a selective femoral vasodilator, is an alpha2C-adrenoceptor-selective antagonist.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Alprostadil; Aniline Compounds; Animals; CHO Cells; Cloning, Molecular; Cricetinae; Femoral Vein; Hindlimb; In Situ Hybridization; In Vitro Techniques; Luciferases; Male; Piperidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Vasodilator Agents; Yohimbine | 2001 |
alpha(2)-adrenoceptor antagonist properties of OPC-28326, a novel selective peripheral vasodilator.
Topics: Adrenergic alpha-Antagonists; Aniline Compounds; Animals; Azepines; Binding, Competitive; Blood Pressure; Brimonidine Tartrate; Decerebrate State; Dose-Response Relationship, Drug; In Vitro Techniques; Male; Muscle Contraction; Mydriasis; Piperidines; Quinoxalines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Synaptic Transmission; Vas Deferens; Vasodilator Agents; Yohimbine | 2001 |
Neurogenic double-peaked vasoconstriction of human gastroepiploic artery is mediated by both alpha1- and alpha2-adrenoceptors.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aniline Compounds; Dose-Response Relationship, Drug; Drug Interactions; Electric Stimulation; Female; Gastroepiploic Artery; Humans; Male; Middle Aged; Norepinephrine; Perfusion; Piperidines; Prazosin; Receptors, Adrenergic, alpha; Time Factors; Vasoconstriction; Vasoconstrictor Agents; Vasodilator Agents; Yohimbine | 2005 |